These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29679316)

  • 21. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
    Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
    Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH
    Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
    Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G
    Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
    Goldie SJ; Kohli M; Grima D; Weinstein MC; Wright TC; Bosch FX; Franco E
    J Natl Cancer Inst; 2004 Apr; 96(8):604-15. PubMed ID: 15100338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The human papillomavirus vaccination: a review of the cost-effectiveness studies.
    Giraldi G; Martinoli L; De Luca d'Alessandro E
    Clin Ter; 2014; 165(6):e426-32. PubMed ID: 25524200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review of the cost-effectiveness of the vaccination against HPV in Brazil.
    Fonseca AJ; de Lima Ferreira LC
    Hum Vaccin Immunother; 2014; 10(12):3484-90. PubMed ID: 25483692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.
    Ben Hadj Yahia MB; Jouin-Bortolotti A; Dervaux B
    Clin Drug Investig; 2015 Aug; 35(8):471-85. PubMed ID: 26187455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.
    Setiawan D; Luttjeboer J; Westra TA; Wilschut JC; Suwantika AA; Daemen T; Atthobari J; Wilffert B; Postma MJ
    Expert Rev Vaccines; 2015 Apr; 14(4):589-604. PubMed ID: 25482311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
    Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Utility Analysis of Human Papillomavirus Vaccination and Cervical Screening on Cervical Cancer Patient in Indonesia.
    Setiawan D; Dolk FC; Suwantika AA; Westra TA; WIlschut JC; Postma MJ
    Value Health Reg Issues; 2016 May; 9():84-92. PubMed ID: 27881267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effective.
    Zhang L; Regan DG; Ong JJ; Gambhir M; Chow EPF; Zou H; Law M; Hocking J; Fairley CK
    Vaccine; 2017 Sep; 35(37):4923-4929. PubMed ID: 28789853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?
    Isaranuwatchai W; Graham DM; Siu LL; Hoch JS
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):763-5. PubMed ID: 25095728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States.
    Chesson HW; Meites E; Ekwueme DU; Saraiya M; Markowitz LE
    Vaccine; 2018 Jul; 36(29):4362-4368. PubMed ID: 29887325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review.
    Wong CKH; Liao Q; Guo VYW; Xin Y; Lam CLK
    Vaccine; 2017 May; 35(24):3153-3161. PubMed ID: 28476628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru.
    Goldie SJ; Levin C; Mosqueira-Lovón NR; Ortendahl J; Kim J; O'Shea M; Diaz Sanchez M; Mendoza Araujo MA
    Rev Panam Salud Publica; 2012 Dec; 32(6):426-34. PubMed ID: 23370186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
    Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
    J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM; van Ballegooijen M; Habbema JD
    J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.
    Prinja S; Bahuguna P; Faujdar DS; Jyani G; Srinivasan R; Ghoshal S; Suri V; Singh MP; Kumar R
    Cancer; 2017 Sep; 123(17):3253-3260. PubMed ID: 28472550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.